Keros Therapeutics (KROS) awards 80,000 stock options to Chief Legal Officer

Rhea-AI Filing Summary

Keros Therapeutics reported that Chief Legal Officer Esther Cho received a grant of employee stock options covering 80,000 shares of common stock. The options have an exercise price of $15.52 per share and expire on February 23, 2036. One quarter of the options vest on February 24, 2027, with the remaining shares vesting in twelve substantially equal quarterly installments, contingent on her continued service. This is a compensation-related award rather than an open‑market purchase.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Cho Esther

Role Chief Legal Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	80,000	$0.00	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 80,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cho Esther

(Last) (First) (Middle)

C/O KEROS THERAPEUTICS, INC.

1050 WALTHAM STREET, SUITE 302

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Keros Therapeutics, Inc. [ KROS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
02/26/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$15.52	02/24/2026		A		80,000		(1)	02/23/2036	Common Stock	80,000	$0	80,000	D

Explanation of Responses:

1. One-fourth (1/4th) of the shares subject to the option shall vest on February 24, 2027, and the remaining shares subject to the option shall vest in twelve substantially equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

Remarks:

This filing amends and restates the Form 4 filed on February 26, 2026 that erroneously reported a Date of Earliest Transaction of January 5, 2026 due to an error with the filing platform.

	/s/ Esther Cho	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Keros Therapeutics (KROS) report for Esther Cho?

Keros Therapeutics reported a compensation-related grant to Chief Legal Officer Esther Cho of options on 80,000 common shares. These employee stock options were awarded at no upfront cost, providing the right to buy shares at a fixed exercise price over time, subject to vesting.

What are the key terms of Esther Cho’s stock option grant at Keros Therapeutics (KROS)?

The grant covers 80,000 options with an exercise price of $15.52 per share and an expiration date of February 23, 2036. It is structured as an employee stock option, giving her the right, but not obligation, to purchase common shares in the future.

How do Esther Cho’s Keros Therapeutics (KROS) options vest over time?

One-fourth of the 80,000 options vest on February 24, 2027. The remaining options vest in twelve substantially equal quarterly installments after that date, provided she continues to provide service to the company through each scheduled vesting date.

Is Esther Cho’s Form 4/A transaction in Keros Therapeutics (KROS) an open-market purchase or sale?

The Form 4/A shows a grant classified as an acquisition under code “A,” reflecting a stock option award, not an open-market buy or sell. She incurred no purchase cost at grant; the exercise price applies only if she later chooses to exercise.

How many Keros Therapeutics (KROS) derivative securities does Esther Cho hold after this transaction?

After this stock option grant, the filing shows Esther Cho holding 80,000 derivative securities related to common stock. These represent options, not currently owned shares, and become exercisable only as they vest and before the stated expiration date, under the award’s terms.